BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32886456)

  • 1. From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?
    Chen Q; Mao R; Zhao J; Bi X; Li Z; Huang Z; Zhang Y; Zhou J; Zhao H; Cai J
    Cancer Med; 2020 Nov; 9(21):7849-7862. PubMed ID: 32886456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Time to Surgery of Colorectal Liver Metastases on Survival.
    Chen EY; Mayo SC; Sutton T; Kearney MR; Kardosh A; Vaccaro GM; Billingsley KG; Lopez CD
    J Gastrointest Cancer; 2021 Mar; 52(1):169-176. PubMed ID: 32086781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the optimal number of neoadjuvant chemotherapy cycles for resectable colorectal liver oligometastases?
    Chen Q; Li X; Zhao J; Bi X; Li Z; Huang Z; Zhang Y; Zhou J; Zhao H; Cai J
    Ann Transl Med; 2021 Jan; 9(1):7. PubMed ID: 33553300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neo-adjuvant Chemotherapy-Induced Neutropenia Is Associated with Histological Responses and Outcomes after the Resection of Colorectal Liver Metastases.
    Chen Q; Wu C; Zhao H; Wu J; Zhao J; Bi X; Li Z; Huang Z; Zhang Y; Zhou J; Cai J
    J Gastrointest Surg; 2020 Mar; 24(3):659-670. PubMed ID: 30937711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of follow-up treatment regimens for colorectal cancer liver metastases without objective response to neoadjuvant chemotherapy: direct surgery or surgery after second-line chemotherapy].
    Lyu XY; Bi XY; Zhao H; Chen QC; Luo ZW; Zhang BL; Zhang XS; Cai JQ
    Zhonghua Wai Ke Za Zhi; 2022 May; 60(5):454-460. PubMed ID: 35359087
    [No Abstract]   [Full Text] [Related]  

  • 6. Morphological aspects of the hepatic response to neoadjuvant therapy.
    Fernández-Aceñero MJ; Cortés-Guiral D; Muñoz LE; Martínez-Useros J; Pastor-Idoate C
    Pathol Res Pract; 2015 Sep; 211(9):665-70. PubMed ID: 26163186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
    Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB
    Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative study on prognosis of neoadjuvant chemotherapy followed by hepatic surgery versus upfront surgery in patients with synchronous colorectal liver metastasis].
    Wang LJ; Wang HW; Jin KM; Liu W; Bao Q; Wang K; Xing BC
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):248-255. PubMed ID: 34645169
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimal surgical sequence for colorectal cancer liver metastases patients receiving colorectal cancer resection with simultaneous liver metastasis resection: A multicentre retrospective propensity score matching study.
    Chen Q; Zhang R; Xing B; Li C; Xiu D; Chen J; Deng Y; Chen X; Guo R; Chen F; Peng J; Sun T; Wang H; Li M; Zheng Q; Bi X; Zhao J; Zhou J; Li Z; Huang Z; Zhang Y; Zhang Y; Cai J; Zhao H
    Int J Surg; 2022 Oct; 106():106952. PubMed ID: 36220519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CALy Prognostic Score (CEA, ALP, Lymphocyte Count) as a predictor of survival after hepatectomy for liver-only colorectal metastases.
    Neofytou K; Giakoustidis A; Mudan S
    J BUON; 2015; 20(3):746-55. PubMed ID: 26214626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases.
    Khoo E; O'Neill S; Brown E; Wigmore SJ; Harrison EM
    HPB (Oxford); 2016 Jun; 18(6):485-93. PubMed ID: 27317952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between imaging response and survival following neoadjuvant chemotherapy in patients with resectable colorectal liver metastases: A cohort study.
    Behrenbruch C; Prabhakaran S; Udayasiri D D; Michael M; Hollande F; Hayes I; Heriot AG; Knowles B; Thomson BN
    J Surg Oncol; 2021 Apr; 123(5):1263-1273. PubMed ID: 33524184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of margin status and neoadjuvant chemotherapy on survival, recurrence after liver resection for colorectal liver metastasis.
    Pandanaboyana S; White A; Pathak S; Hidalgo EL; Toogood G; Lodge JP; Prasad KR
    Ann Surg Oncol; 2015 Jan; 22(1):173-9. PubMed ID: 25084766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials.
    Moretto R; Corallo S; Belfiore A; Rossini D; Boccaccino A; Lonardi S; Centonze G; Morano F; Germani MM; Loupakis F; Morelli L; Urbani L; Brich S; Marmorino F; Prisciandaro M; Aprile G; Fassan M; Cillo U; Cattaneo L; Fontanini G; De Braud F; Falcone A; Milione M; Pietrantonio F; Cremolini C
    Eur J Cancer; 2020 Aug; 135():78-88. PubMed ID: 32554314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An elevated preoperative cholesterol-to-lymphocyte ratio predicts unfavourable outcomes in colorectal cancer liver metastasis patients receiving simultaneous resections: a retrospective study.
    Deng Y; Chen Q; Chen J; Zhang Y; Zhao J; Bi X; Li Z; Zhang Y; Huang Z; Cai J; Zhao H
    BMC Surg; 2023 May; 23(1):131. PubMed ID: 37194000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial.
    Buisman FE; Homs MYV; Grünhagen DJ; Filipe WF; Bennink RJ; Besselink MGH; Borel Rinkes IHM; Bruijnen RCG; Cercek A; D'Angelica MI; van Delden OM; Donswijk ML; van Doorn L; Doornebosch PG; Emmering J; Erdmann JI; IJzerman NS; Grootscholten C; Hagendoorn J; Kemeny NE; Kingham TP; Klompenhouwer EG; Kok NFM; Koolen S; Kuhlmann KFD; Kuiper MC; Lam MGE; Mathijssen RHJ; Moelker A; Oomen-de Hoop E; Punt CJA; Te Riele WW; Roodhart JML; Swijnenburg RJ; Prevoo W; Tanis PJ; Vermaas M; Versleijen MWJ; Veuger FP; Weterman MJ; Verhoef C; Groot Koerkamp B
    BMC Cancer; 2019 Apr; 19(1):327. PubMed ID: 30953467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rebound growth of hepatic colorectal metastases after neo-adjuvant chemotherapy: effect on survival after resection.
    Lim E; Wiggans MG; Shahtahmassebi G; Aroori S; Bowles MJ; Briggs CD; Stell DA
    HPB (Oxford); 2016 Jul; 18(7):586-92. PubMed ID: 27346139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Chemotherapy Followed by Radiofrequency Ablation Prolongs Survival for Ablatable Colorectal Liver Metastasis: A Propensity Score Matching Comparative Study.
    Chen Y; Xu Y; Xu L; Han F; Huang Y; Jiang H; Wu J; Zhang Y
    Front Oncol; 2021; 11():758552. PubMed ID: 34745996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to surgery following neoadjuvant chemotherapy for breast cancer impacts residual cancer burden, recurrence, and survival.
    Sutton TL; Schlitt A; Gardiner SK; Johnson N; Garreau JR
    J Surg Oncol; 2020 Dec; 122(8):1761-1769. PubMed ID: 33125715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical relevance of the Fong and the Nordlinger scores in the era of effective neoadjuvant chemotherapy for colorectal liver metastasis.
    Schreckenbach T; Malkomes P; Bechstein WO; Woeste G; Schnitzbauer AA; Ulrich F
    Surg Today; 2015 Dec; 45(12):1527-34. PubMed ID: 25563588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.